Skip to main content

Priorix FDA Approval History

Last updated by Judith Stewart, BPharm on June 8, 2022.

FDA Approved: Yes (First approved June 3, 2022)
Brand name: Priorix
Generic name: measles, mumps, and rubella virus vaccine, live
Dosage form: Injection
Company: GlaxoSmithKline
Treatment for: Measles Prophylaxis, Mumps Prophylaxis, Rubella Prophylaxis

Priorix (measles, mumps, and rubella virus vaccine, live) is a live attenuated vaccine for use in active immunization against infection by measles, mumps and rubella (MMR).

Development timeline for Priorix

Jun  6, 2022Approval FDA Approves Priorix (Measles, Mumps and Rubella Vaccine, Live) for the Prevention of Measles, Mumps and Rubella in Individuals 12 Months of Age and Older
Aug  2, 2021GSK Files for Licensure of Priorix MMR Vaccine in the US

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.